

# Clinical Profile and One Year Outcome of Atrial Fibrillation- A Prospective Cohort Study

PRAVEEN SATHEESAN<sup>1</sup>, VEENA FELIX<sup>2</sup>, ALUMMOOTTIL GEORGE KOSHY<sup>3</sup>

## ABSTRACT

**Introduction:** Atrial Fibrillation (AF) is the most common arrhythmia in clinical practice and imposes a great burden on health care resources. There is limited data regarding the impact of AF in our population.

**Aim:** To estimate the mortality and Major adverse Cardiovascular events {(MACE)- Acute Coronary Syndrome (ACS), Stroke, Cardiac death} in AF patients in a tertiary care centre in South India.

**Materials and Methods:** This prospective cohort study included all patients >18 years with newly diagnosed or previously documented evidence of AF in Electrocardiography (ECG). Transient reversible causes and critically ill patients were excluded. Total of 346 patients were recruited and prospectively, followed-up at 1, 3, 6 and 12 months for development of MACE, anticoagulation status, Prothrombin Time (PT), International Normalised Ratio (INR) and major bleeding events. Baseline data including clinical parameters, comorbidities and appropriate investigations such as ECG and Echocardiogram (ECHO) parameters were collected with a structured questionnaire and analysed at one year using appropriate statistical tests.

**Results:** Average age was 60.5 years (SD 11.5 years) and majority (74.6%) were between 50-75 years. Females were more (59.5% vs 40.5%). Most common AF risk factor was Hypertension (44.5%) followed by Rheumatic Heart Disease (RHD) in 27.2% of AF patients. AF was classified as permanent in 42.2%, persistent in 23.1% and paroxysmal in 34.7%. Valvular AF was present in 26.6% and non-valvular AF in 73.4%. At one year, 17 patients were lost to follow-up. CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$  was present in 65.1%. During one year follow-up the MACE rate was 26.7% (ischemic stroke in 9.4%, ACS in 2.7% and cardiac mortality in 14.6%). Mean time in Therapeutic Range (TTR) was 28.12%. TTR >60% (good control) was present in only 9.2%.

**Conclusion:** AF continues to be a significant arrhythmia causing substantial morbidity and mortality. Non-valvular AF was thrice as common as valvular AF. Though 3/4<sup>th</sup> of the patients were on oral anticoagulants, <10% had their INR under good control which contributed to the higher events. To improve the outcomes in AF patients, treatment of risk factors and optimal anticoagulation plays a crucial role.

**Keywords:** Anticoagulants, Arrhythmia, Thromboembolism

## INTRODUCTION

AF is characterised by uncoordinated atrial activation with subsequent deterioration of atrial mechanical function. AF is the most common arrhythmia for which patients are hospitalised; approximately 33% of arrhythmia-related hospitalisations are for AF. Global prevalence is estimated to be 0.47%, but there is significant regional variation [1].

Hypertension is the most common comorbidity identified in 56.3% of AF patients [2]. In India, RHD had been the significant contributing factor for AF [3]. Valvular Heart Disease (VHD) is independently associated with incident AF [4] and approximately 30% of patients with AF have some form of VHD, often detected only by echocardiogram [5-8].

There is a greater prevalence in older persons and in heart failure, Coronary Artery Disease (CAD), VHD, obesity, diabetes, or Chronic Kidney Disease (CKD) [1,9-15]. AF genesis requires a vulnerable atrial substrate. Increased atrial pressure, volume overload and atrial structural remodeling, together with activation of the sympathetic and renin-angiotensin system causes AF in patients with structural heart disease. Some AF patients have no or minimal symptoms (25-40%), while many (15-30%) report severe or disabling symptoms [16,17].

Patterns of AF may vary from paroxysmal to persistent and permanent AF depending on the duration and mode of termination [Table/Fig-1]. The first documentation of AF is important as the treatment strategy depends on this. One must recognise that it may be asymptomatic and just a chance detection. It may be self-limited and do not tell about the duration of that particular episode, and neither does it preclude undetected episodes before the index episode. Only 10% of AF patients remained free of AF two years after incident AF, and recurrent (26%) or sustained AF (34%) were common [18].

Paroxysmal AF	Termination within seven days, in most cases within 48 hours. From therapeutic angle, after 48 hours, chance of termination drastically falls and preconversion anticoagulation becomes necessary. AF episodes that are cardioverted within seven days are also included.
Persistent AF	AF that lasts longer than seven days, including termination by cardioversion after seven days or more.
Permanent AF	AF that is accepted by the patient and physician and Rhythm control interventions are not pursued.

[Table/Fig-1]: Patterns of Atrial Fibrillation (AF).

In the Realise-AF survey which recruited 301 patients, it was found that the concomitant cardiovascular risk factors were high and the AF control was highly inadequate [19]. In the Nagpur pilot study, it was found that the AF prevalence was low compared to previous studies and that stroke prophylaxis was under utilised [20]. The Indian Heart Rhythm Society-AF (IHRS-AF) Registry of 1537 patients showed a significant mortality and morbidity in Indian patients due to AF [21].

Regional variation in healthcare systems, resource availability and physician preferences influence the therapies applied. Although the effect of AF on the quality of life and survival has been well documented in western population, similar data on incidence, prevalence, aetiology, mortality and morbidity in the Indian population is limited.

Hence, the primary aim of the present study is to estimate the incidence of MACE- ACS, cardiac death, stroke in patients with AF on one year follow-up.

The secondary objectives of the study include

- (1) To assess the common comorbidities associated with AF.

- (2) To document the anticoagulation strategy in AF patients.
- (3) To estimate the overall mortality in AF patients.

## MATERIALS AND METHODS

This prospective cohort study included all patients above the age of 18 years with newly diagnosed AF between April 2016-March 2017 or previously documented (before April 2016) evidence of AF in ECG who presented or was admitted in the department of Cardiology, Trivandrum Medical College. Institutional Ethics Committee clearance was obtained (HEC.No.01/20/2016/MCT). Study procedures were in accordance with Helsinki Declaration. Informed written consent obtained from participants in their mother tongue.

Sample size was calculated using the below formula [22],  $p=8.8\%$  (proportion of stroke among AF patients) with reference to the CHA<sub>2</sub>DS<sub>2</sub>VASc score Birmingham 2009 validation study [23].

$p$ : Expected proportion (8.8%)

$\delta$ : Absolute precision (3%)

$1 - \frac{\alpha}{2}$ : Desired Confidence level=(95%)

$$n = \frac{z^2 \cdot \frac{\alpha}{2} \cdot p(1-p)}{\delta^2} = 314$$

Transient AF due to reversible causes like during acute myocardial infarction, infection, metabolic abnormalities, alcohol intoxication, postoperative AF, critically ill patients with life expectancy less than seven days and those who did not give consent for enrolling into this study were excluded.

### Study Method

Patients who presented with AF, either as the primary reason for their visit or as secondary diagnosis fulfilling the inclusion criteria were registered. Clinical data were collected by interviews with patients and review of medical records. At baseline, available data were collected based on the following points: patient demographics, medical history, type of AF (Valvular AF- moderate to severe Mitral stenosis, Mechanical Prosthetic Heart Valves and non-valvular AF- all others), date of diagnosis, symptoms, past events and treatment decisions. The diagnosis of all medical conditions including type of AF was based on the clinical records. Patients having AF was diagnosed by their ECG showing irregularly irregular QRS complex with no preceding P waves. Relevant blood investigations such as blood counts, renal parameters, liver function test, blood glucose, electrolytes, thyroid function tests, PT and INR, ECG and ECHO parameters were noted at baseline. Patients were followed-up at 1, 3, 6 and 12 months for symptoms, treatment adherence, investigations such as PT, INR, development of complications such as ACS, stroke, Transient Ischemic Attack (TIA), bleeding manifestations, and clinical course. For patients on oral anti-coagulation, the INR values at 1, 3, 6 and 12 months were collected. In patients with at least two available INR values, the degree of INR control was calculated and presented as the TTR by Traditional Method (i.e., Percentage of visits in range) [24]. It presents that how many visits had INR results in range, and divides by the total number of visits. Major bleeding is defined according to the International Society of Thrombosis and Haemostasis Bleeding Scale as fatal bleeding or symptomatic bleeding in a critical organ such as intracranial, intraocular, retroperitoneal, intraarticular or intramuscular with compartment syndrome or fall in Haemoglobin by  $\geq 2$  g/dL or requiring transfusion of  $\geq 2$  units of whole blood or red cells [25]. Data was collected from patients and bystanders using a semi-structured questionnaire-based interview [Annexure], clinical examination, lab investigations and telephonic follow-up. Investigations such as blood counts, renal parameters, liver function test, blood glucose, electrolytes, PT and INR, ECG and ECHO (Philips EPIQ 7) parameters were noted at baseline. Patients were followed-up with PT/INR values at follow-up visits, either by hospital

visits or telephonic follow-up. The CHA<sub>2</sub>DS<sub>2</sub>VASc score [Table/Fig-2] was used to assess the risk of thromboembolism and to decide on anticoagulation in non-valvular AF.

Presence of risk factor	Score
Congestive heart failure	1 point
Hypertension	1 point
Age >75 years	2 points
Diabetes mellitus	1 point
Stroke/TIA	2 points
Vascular disease	1 point
Age 65-74 years	1 point
Sex (female)	1 point

**[Table/Fig-2]:** Calculation of CHA<sub>2</sub>DS<sub>2</sub>VASc Score.  
TIA: Transient Ischemic Attack

Presence of each of the risk factor attributes to the above given points and the total points added up to get the CHA<sub>2</sub>DS<sub>2</sub>VASc score which predicts the risk of thromboembolism in Non-valvular-AF patients and aids in deciding anticoagulation therapy.

## STATISTICAL ANALYSIS

All data are expressed as mean and standard deviation. Data were summarised in subgroups using measures of central tendency and dispersion, number of patients for continuous data and as count and percentage for categorical data. Data analysis was done with the help of Excel 2010 statistical software.

## RESULTS

There were total of 346 patients with AF in this study. Average age of the patients was 60.5 years (SD of 11.5 years) with age ranging from 22 years to 87 years [Table/Fig-3]. Females outnumbered males and constituted 59.5% of the study population. Overall, hypertension was the most prevalent comorbid condition (44.5%). History of VHD was present in 38.2% (n=132) of the patients, out of which 27.2% (n=94) were due to RHD. Dilated Cardiomyopathy, Hypertrophic and Restrictive cardiomyopathy were present in 5.2%, 1.7% and 0.6% of the study population, respectively. CAD was present in 20.2% of which 20% (n=14) of CAD patients had undergone Percutaneous Coronary Intervention (PCI). Cardiac surgery which included Mitral Valvotomy, Valve Replacement and Coronary Artery Bypass Graft (CABG) constituted 9.2% (n=32) and congenital heart disease patients formed only 1.7% (n=6) of the study population [Table/Fig-4]. Electrocardiogram findings include significant Q wave in 6.9% of the patients, Left Bundle Branch Block (LBBB) in 4%, Left Ventricular Hypertrophy (LVH) in 19.7% and 23.7% had significant ST-T changes.

Age in years	Frequency	Percentage
<50	54	15.6
50-74	258	74.6
>75	34	9.8
Total	346	100

**[Table/Fig-3]:** Age distribution of AF patients.


Echocardiogram findings include Left Atrial (LA) dilatation (LA diameter  $\geq 4$  cm) in 65.03% of the patients. Regional wall motion abnormality was present in 12.7% (44 patients) and Left Ventricular dysfunction (LV ejection fraction  $<50\%$ ) was present in 34.4% of patients [Table/Fig-5]. Mitral stenosis (Mitral valve area  $<1.5$  cm<sup>2</sup>) was present in 23.1% (n=80); all were due to RHD. Aortic stenosis was present in 4% (n=14). Mitral Regurgitation in 29.5% (n=102) and Aortic Regurgitation in 8.7% (n=30). LV Hypertrophy was present in 29.2% (n=101) and Pulmonary Hypertension in 25.4% (n=88).

In total, 74% (n=256) received oral anticoagulants (vitamin K antagonists). All patients were on vitamin K antagonists and none

Baseline characteristics	Value (n)	Percentage
Male	140	40.5%
Female	206	59.5%
Hypertension	154	44.5%
RHD	94	27.2%
CAD	70	20.2%
COPD/Asthma	48	13.9%
Hypothyroid	26	7.5%
Hyperthyroid	10	2.9%
Diabetes	68	19.7%
Cardiomyopathy (Total)	26	7.5%
-Dilated cardiomyopathy	18	5.2%
-Hypertrophic cardiomyopathy	6	1.7%
-Restrictive cardiomyopathy	2	0.6%
Previous cardiac surgery	32	9.2%
Congenital heart disease	6	1.7%
Chronic kidney diseases	16	4.6%

**[Table/Fig-4]:** Baseline characteristics.

RHD: Rheumatic heart disease; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease



**[Table/Fig-5]:** Distribution of LV systolic function.

EF: Ejection fraction; Y axis: number of Patients; X-axis: EF distribution

were on Novel Oral Anticoagulants (NOACs). The CHA<sub>2</sub>DS<sub>2</sub>-VASc score was used in 67.9% to assess the risk of thromboembolism and to decide on anticoagulation in non-valvular AF. Aspirin was given to 34.7% of the patients (n=120) and 9% of the patients were on dual anti platelet therapy. Beta blockers (n=290) and Digoxin (n=88) were the most commonly used drugs for rate control. Angiotensin Converting Enzyme (ACE) inhibitors (26.6%), Angiotensin II Receptor Blockers (ARBs) (13.9%) and diuretics (43.9%) were the other commonly used drugs. Total of 12 patients had Permanent Pacemaker Implanted (PPI), the primary indication being Sick Sinus Syndrome (SSS).

Time in Therapeutic Range (TTR) with INR values between 2 to 3 was calculated by Traditional method. Only a single INR value was available in 23 patients. TTR ≥50% was present in 40.9% patients. TTR >60% (good control) was present in only 9.2% of the study population. Intermediate control (TTR 50-60%) was noted in 31.7% and poor control (<50%) in 59.1% of the patients [Table/Fig-6]. Mean TTR was 28.12%.

TTR	Frequency (total=186)	Percent
0%	49	26.3%
25%	61	32.8%
50%	59	31.7%
75%	15	8.1%
100%	2	1.1%
Total	186	100%

**[Table/Fig-6]:** Time in Therapeutic Range (TTR).

During the follow-up period of one year, 17 patients were lost to follow-up. Of the study population, 14.6% had AF related death

[Table/Fig-7]. Embolic stroke developed in 9.4% of the patients and ACS occurred in 2.7%. None of the patients had peripheral embolisation. MACE occurred in total of 26.7% of AF patients. Major bleeding occurred in 8.8% of the patients. Overall, mortality during the study period was 15.8% of which four deaths were unrelated to AF.

Events	1 month (n)	3 months (n)	6 months (n)	12 months (n) (%)
Overall MACE	9	28	47	88 (26.7)
ACS	0	2	5	9 (2.7%)
Cardiac death	5	11	19	48 (14.6%)
Stroke (Embolic) /TIA	4	15	23	31 (9.4%)
Death	5	12	21	52 (15.8%)
Major bleeding	2	6	17	29 (8.8%)
Peripheral embolism	0	0	0	0
Intracranial haemorrhage	0	1	1	2 (0.6%)

**[Table/Fig-7]:** MACE and major complications on follow-up (n=329).

MACE: Major adverse Cardiovascular events; ACS: Acute Coronary Syndrome; TIA: Transient Ischemic Attack

## DISCUSSION

The incidence of AF increases with advancing age. In this study, more than two third of the patients were above 50 years. Mean age was 60.5±11.5 years. AF is the most common sustained arrhythmia present in 3-5% of those >65 years of age [4,26]. Average age in the RELY-AF Registry was 65.9±14.8 years [14] and in the recent IHRS AF registry [21] which enrolled 1537 AF patients mean age of the entire Indian cohort was 54.7±15.9 years. In this study, the proportion of females (59.5%) were more, as in the IHRS-AF registry (51.5%) [21].

Hypertension is the most common risk factor for AF, globally. In this study, hypertension was present in 44.5%. Hypertension was identified in 41.6% of Indian AF patients in the RELY-AF Registry [14] and in 31.4% in the IHRS-AF registry [21]. Hypertension is most likely to be untreated and poorly controlled and in this study, 19.7% patients had evidence of LV hypertrophy; a marker of prolonged uncontrolled hypertension and poor outcomes. This leads to elevated LV end diastolic pressures, diastolic dysfunction and elevated LA pressures leading to Atrial dilatation and AF. Thus, effective strategies to detect, treat and control hypertension need to be implemented to prevent AF.

RHD remains an important cause of AF in India. In this study, 26.6% of patients had ECHO evidence of moderate to severe VHD of Rheumatic aetiology of which majority were contributed by Mitral Stenosis. Thus, VHD attributed to one third of the cases, while it was the commonest cause (47.6%) in IHRS-AF Registry [21]. In RELY-AF Registry, it was present in 31.5% of AF patients in India [14]. Mitral stenosis patients with AF are at a higher New York Heart Association (NYHA) class of dyspnoea and show greater LA enlargement. The other attributing factors for thrombus formation in AF are Heart Failure present in 20.8%, diabetes in 19.7% and CAD in 20.2% in the present study. In IHRS-AF study, these figures were 18.7%, 16.1% and 16.2%, respectively [21].

In patients with enlarged and dysfunctional atria, despite correction of the underlying valvular lesion, AF often persists. In this study, 9.2% of patients had undergone previous cardiac surgery. Strategies for early diagnosis and preventing the development and recurrence of RHD have a great impact on preventing AF and its complications [27].

Paroxysmal episodes of non-valvular AF remain as paroxysmal for long periods and rarely progress to persistent. However, though the valvular AF begins as paroxysmal episodes, they rapidly progress to persistent AF. There was a substantial variation in the type of AF in various studies. In RELY-AF Registry paroxysmal AF was present in 20.5%, persistent in 32.9% and permanent in 46.6% [14]. While in the IHRS AF Registry paroxysmal, persistent and permanent were 20.4%, 33.0% and 35.1%, respectively [21]. In present study group

it was 34.7%, 23.1% and 42.2%, respectively. In this study, Valvular AF (Moderate to Severe Mitral Stenosis and Mechanical Prosthetic Valve) constituted 26.6% and Non-valvular AF in 73.4%.

Occurrence of AF correlates with LA size; incidence rises from 3% when LA diameter is <40 mm to 54% when LA diameter is >40 mm [28]. LA enlargement was present in 65.03% of AF patients in this study. Chronic AF per say can cause Atrial enlargement.

AF is a major cause of systemic thromboembolism. In patients over the age of 65 years, it is responsible for more than one third of all strokes [29]. Advancing age, previous thromboembolic events, presence of VHD, heart failure, enlarged LA, previous MI, hypertension and LA thrombus on echocardiography predict occurrence of embolic stroke in patients with AF [30]. Presence of AF multiplies the risk of stroke five times in a patient with structurally normal heart, and increases by a factor of 17 in those with VHD. Risk of recurrent strokes appears to be similar with chronic and paroxysmal AF.

The appropriate use of oral anticoagulation can reduce the rate of stroke by two third. Current ESC guidelines recommend that in Non-valvular AF, if the patient has a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$ , anticoagulants are indicated to reduce thromboembolic events [23]. Vast majority of the non-valvular AF patients had a high CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$  (65.1%) almost similar (68.5%) to that in IHRS-AF registry [21]. However, OAC were prescribed for only 58% of these patients with non-valvular AF and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$  in the RELY AF Registry [14]. In this study, OACs were not used in 32.9% of non-valvular AF with CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq 2$ , and the rest 67.1% received OAC. In patients with VHD all were on OAC. In total 74% of all AF patients were on OAC. There was also a tendency to under anticoagulate. Good control (TTR >60%) was present in only 9.2%. Use of OACs and proper dosing in these AF patients at risk for stroke are limited by infrequent access to INR testing, irregular follow-up visits, increased risk of bleeding and non-compliance to medication.

In addition to lowering of stroke risk, there is evidence that Warfarin leads to less severe stroke episodes and lowers the 30-day stroke mortality [31]. In RELY study, INR control was particularly poor in India, China and Southeast Asia with mean TTR of 33.7% [14]. Present study has a mean TTR of 28.12%. NOACs help to overcome some of these barriers; however, high costs make them affordable for only few patients. Although aspirin is less effective than oral anticoagulants, it does not require regular monitoring and is affordable, thereby though not ideal but is still better than no stroke prevention therapy at all.

Important safety issue with the use of anticoagulants is the increased risk of major bleeding leading to hospitalisation, transfusion, surgery, or involving crucial anatomic locations. Major bleed occurred in 8.8% of patients during one year follow-up. Intracranial Haemorrhage (ICH) is the most serious bleeding complication accounting for high morbidity and mortality. ICH in anticoagulated population occurs at a rate of 0.2% to 1.0% per year [32]. This study had two patients (0.6%) who developed ICH.

The management of AF is aimed at either control of ventricular rate without attempting to restore sinus rhythm, or restoration to sinus rhythm with follow-up aggressive therapy to maintain it. Rhythm-control strategy offers no survival advantage over the rate-control strategy (which has lower risk of adverse drug effects). In both approaches, the use of anticoagulant drugs is recommended [33]. In this study, rate control strategy was adopted in 93.6% and only 5.8% had rhythm control.

In this study, at one year follow-up, MACE occurred in 26.7%, which is higher than that in a previous study conducted in China (one-year MACE was 21.9%) [34]. Stroke occurred in 9.4% while 1.03% patients had stroke in the IHRS-AF Registry [21]. Of these patients who developed stroke in this study, 90.32% were on OAC and 6 patients had CHA<sub>2</sub>DS<sub>2</sub>-VASc score <2. Subtherapeutic INR and drug

default were the contributors for this high rate of stroke. A study by Healey JS et al., showed one-year mortality rate of around 11-20%, with heart failure being the most common cause of death [35]. In this study, AF related death occurred in 14.6% with heart failure being the commonest cause for the death. While in the IHRS-AF registry, the mortality at one year was 6.5% with heart failure being the commonest cause [21]. ACS accounted to 14% of the mortality in IHRS-AF registry [21]. In this study, ACS occurred in 2.7% of the AF patients and attributed to 3.8% of the total mortality.

### Limitation(s)

The possibility of selection bias cannot be excluded as each consecutive patients presenting to the cardiology department could not be recruited. This study represents patients from a tertiary care centre, managed by cardiologists hence confounds the community incidence and prevalence of AF.

### CONCLUSION(S)

In contrast to the previous studies non-valvular AF was thrice as common as valvular AF. Though three fourth of the patients were on oral anticoagulants, <10% had their INR under good control. The follow-up data shows high mortality and event rates in this cohort of patients due to subtherapeutic anticoagulation. This study underlines the importance of early detection and treatment of underlying risk factors of AF. Patients on OAC, particularly VKAs have to do frequent monitoring of INR to ensure adequate anticoagulation. The advent of NOACs with a superior anticoagulation profile is definitely a boon for AF patients particularly in view of the need for prolonged duration of therapy.

### REFERENCES

- [1] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. *Circulation*. 2014;129(8):837-47.
- [2] Gorczyca-Michta I, Wożakowska-Kapłon B, Tomasik E. Prevalence and predisposing conditions for atrial fibrillation in hospitalised patients with hypertension. *Kardiol Pol*. 2013;71(4):352-58.
- [3] Bhardwaj R. Atrial fibrillation in a tertiary care institute- A prospective study. *Indian Heart J*. 2012;64(5):476-78.
- [4] Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). *Am J Cardiol*. 1994;74(3):236-41.
- [5] Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J*. 2012;33(19):2451-96.
- [6] Nishimura RA, Otto C, Bonow R, Carabello B, Erwin JI, Guyton R. AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63:2438-88.
- [7] Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: A prospective survey in ESC Member Countries. *Eur Heart J*. 2005;26(22):2422-34.
- [8] Moretti M, Fabris E, Morosin M, Merlo M, Barbati G, Pinamonti B, et al. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction. *Am J Cardiol*. 2014;114(11):1722-28.
- [9] Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. *Clin Epidemiol*. 2014;6:213-20.
- [10] McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. *Circulation*. 2012;126:e143-46.
- [11] Ball J, Carrington MJ, McMurray JJV, Stewart S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21<sup>st</sup> century. *Int J Cardiol*. 2013;167(5):1807-24.
- [12] Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates 11 Reprints are not available. *Am J Cardiol*. 1998;82(7, Supplement 1):2N-9N.
- [13] Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. *Int J Cardiol*. 2013;167(6):2412-20.
- [14] Jonas O, Healey Jeff S, Michael E, Patrick C, Alvaro A, Prem P, et al. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. *Circulation*. 2014;129(15):1568-76.
- [15] Chiang CE, Lisa NB, Murin J, Goethals M, Inoue H, O'Neill J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice. *Circ Arrhythm Electrophysiol*. 2012;5(4):632-39.
- [16] Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the Prevention of thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF). *Europace*. 2014;16(1):06-14.

- [17] Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes. *Circ Cardiovasc Qual Outcomes*. 2015;8(4):393-402.
- [18] Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. *J Am Heart Assoc*. 2013;2(5):e000126.
- [19] Narasimhan C, Verma JS, Ravi Kishore AG, Singh B, Dani S, Chawala K, et al. Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from Realise AF survey. *Indian Heart J*. 2016;68(5):663-70.
- [20] Saggi DK, Sundar G, Nair SG, Bhargava VC, Lalukota K, Chennapragada S, et al. Prevalence of atrial fibrillation in an urban population in India: The Nagpur pilot study. *Heart Asia*. 2016;8(1):56-59.
- [21] Vora A, Kapoor A, Nair M, Lokhandwala Y, Narsimhan C, Ravikishore AG, et al. Clinical presentation, management, and outcomes in the Indian Heart Rhythm Society-Atrial Fibrillation (IHRSAF) registry. *Indian Heart J*. 2017;69(1):43-47.
- [22] Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of sample size in health studies. Organization WHO. Chichester: Wiley; 1990.
- [23] Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263-72.
- [24] Siddiqui S, Deremer C, Waller J, Gujral J. Variability in the calculation of time in therapeutic range for the quality control measurement of warfarin. *J Innov Card Rhythm Manag*. 2018;9(12):3428-34.
- [25] Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. *J Thromb Haemost*. 2005;3(4):692-94.
- [26] Hill JD, Mottram EM, Killeen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. *J R Coll Gen Pract*. 1987;37(297):172-73.
- [27] Marjon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. *Lancet Lond Engl*. 2012;379(9819):953-64.
- [28] Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. *Circulation*. 1994;89(2):724-30.
- [29] Wipf JE, Lipsky BA. Atrial fibrillation. Thromboembolic risk and indications for anticoagulation. *Arch Intern Med*. 1990;150(8):1598-603.
- [30] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994;154(13):1449-57.
- [31] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146(12):857-67.
- [32] Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. *Neurology*. 2007;68(2):116-21.
- [33] A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. *N Engl J Med*. 2002;347:1825-33.
- [34] Yang Ym, Shao Xh, Zhu J, Zhang H, He Q, Gu Xd. Risk Factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: A national wide database analysis. *International Journal of Cardiology*. 2014;173(2):P242-47.
- [35] Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: A cohort study. *Lancet Lond Engl*. 2016;388(10050):1161-69.

**PARTICULARS OF CONTRIBUTORS:**

1. Associate Professor, Department of Cardiology, Trivandrum Medical College, Thiruvananthapuram, Kerala, India.
2. Assistant Professor, Department of Cardiology, Trivandrum Medical College, Thiruvananthapuram, Kerala, India.
3. Professor, Department of Cardiology, Trivandrum Medical College, Trivandrum, Kerala, India.

**NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:**

Veena Felix,  
GRA-A2, Gandhipuram Road, Chavadimukku, Sreekaryam,  
Thiruvananthapuram-695017, Kerala, India.  
E-mail: dr.veenafelix@gmail.com

**PLAGIARISM CHECKING METHODS:** [\[Jan Het al.\]](#)

- Plagiarism X-checker: Jun 15, 2020
- Manual Googling: Jul 15, 2020
- iThenticate Software: Aug 25, 2020 (18%)

**ETYMOLOGY:** Author Origin**AUTHOR DECLARATION:**

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. Yes

Date of Submission: **Jun 14, 2020**Date of Peer Review: **Jun 25, 2020**Date of Acceptance: **Jul 15, 2020**Date of Publishing: **Sep 01, 2020****Annexure- For recording data**

SL No	
IP/OP No	
Date	
Name and Address	
Phone No	
Gender/Age	
Ht (cm)	
Wt (kg)	
Pulse rate	
SBP/DBP	
H/o SHT (>140/90 mm) or antihypertensives	Y (duration) N                      Unknown
H/o DM	Y (duration) N                      Unknown
H/o Dyslipidemia	Y N                      Unknown
Smoking status	No      Past              Current
Alcohol consumption	No      Past              Current
H/o Rheumatic fever	
H/o Valvular heart disease	No Rheumatic Non-Rheumatic Combined

Valves involved	None		
	Mitral		
	Aortic		
	Combined		
Thyroid disease	No	Hypo	
	Unknown	Hyper	
Chronic heart failure	No		
	HFREF (<50%)		
	HFpEF (>50%)		
NYHA Class	I&II		
	III&IV		
Cardiomyopathy	No		
	DCM		
	HCM		
	RCM		
Known congenital heart disease	No	Cyanotic	Acyanotic
	No		MVR
	CABG		AVR
H/o Cardiac surgery	Double valve replacement		CABG+VR
	CHD repair		Others
	No		Yes Date of Diagnosis
Type of CAD	USA/NSTEMI STEMI/CSA		

Treatment for CAD	Medication alone PCI/CABG/Both	
CAG	Not done	
	SVD	
	DVD	
	Multi VD	
Respiratory Ds		
CKD		
CLD		
Systemic embolism	No	Others
	Stroke	TIA
H/o GI Bleed		
H/o Minor bleed		
Date of first diagnosis of AF		
AF classification	Paroxysmal	
	Persistent	
	Permanent	
Type of AF	Valvular	
	Nonvalvular	
Symptoms	None	
	Palpitation	
	Dyspnoea	
	Chest pain	
	Syncope/presyncope	
	Fatigue	
Duration of symptoms	<48 hrs	
	48 hrs-7 days	
	>1 week	
Main reason for consultation/ admission	AF	
	CAD	
	VHD	
	HT	
	HF	
	Stroke/TIA	
	Peripheral embolism	
	Others	
Used CHA <sub>2</sub> DS <sub>2</sub> VASc/HAS-BLED score in AF	Used none	Used Both
	CHA <sub>2</sub> DS <sub>2</sub> VASc	HAS-BLED
CHA <sub>2</sub> DS <sub>2</sub> VASc	Point	
Symptoms plus objective evidence of HF	0/1	
HT (>140/90 or on drugs)	0/1	
Age	0/1/2	
DM	0/1	
Stroke/TIA/PE (Peripheral embolism)	0/2	
Vascular Ds (MI/PAD)	0/1	
Sex-female	0/1	
Total score		
HAS-BLED score	Point	
HT (uncontrolled SBP >160)	0/1	
Abnormal RFT (Dialysis/Sr Cr >2.26 mg/dL)	0/1	
Abnormal LFT (Cirrhosis/Bi >2 X or OT/PT >3 X normal)	0/1	
Previous stroke	0/1	
Prior major bleed/anemia	0/1	

Labile INR (<60% time in therapeutic range)	0/1		
Age >65	0/1		
Drugs predisposing to bleed	0/1		
Alcohol use	0/1		
Total score			
Strategy of AF treatment	Rhythm control	Rate control	
	If Rhythm control strategy	Betablocker	
Sotalol			
Amiodarone			
Others			
If rate control strategy	Beta blocker		
	Calcium Channel blocker		
	Digoxin		
	Amiodarone		
Other treatments-Catheter ablation, Surgery for AF	Others		
	ECG		
ECG at recruitment	SR/AF/Paced		
Ventricular rate			
Q wave shift S/o MI			
LBBB			
RBBB			
LVH			
LVH with strain			
ST changes			
LAE			
ECHO			
LA size			
LVEF			
LVH			
RWMA			
Mitral stenosis			
Aortic stenosis			
≥Moderate MR			
≥Moderate AR			
≥Moderate PAH			
Rheumatic involvement			
Laboratory Investigations			
Hb			
Chol			
LDL			
HDL			
SGOT			
SGPT			
FBS			
HBA1C			
TSH			
INR			
Bilirubin			
Sr Creatinine			
Medication	Prior medication	While IP	To continue
	Warfarin		
Acitrome			
NOAC (specify)			

Aspirin			
Clopidogrel			
Prasugrel			
Ticagrelor			
Amiodarone			
Beta blocker			
ACE inhibitor			
Digoxin			
ARB			
DHP CCB (Amlol)			

Non DHP CCB			
Diuretics			
Statins			
Others (specify)			
Bridge therapy before VKA	None		
	UFH		
	LMWH		
	Others		
Shifted from VKA to NOAC			
Reason			

### Follow-up Visit

Date		1 month	3 month	6 month	1 year
Contacted	Patient				
	Relative				
Pulse rate					
Heart rate					
Rhythm					
SBP/DBP					
Stroke/TIA					
Other Systemic embolisation					
ACS (treatment given)					
Hospitalisation					
Reason for Hospitalisation Arrhythmia/HF/ACS					
Bleed (GI/ICH/Minor)					
Medication					
None					
Aspirin					
Clopidogrel/Prasugrel/Ticagrelor					
OAC/NOAC					
Warfarin/Acitrom dose					
PT/INR					
Antiarrhythmic drugs					
Cause of death (date/cardiac/stroke/others)					